U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. Cenorin, LLC - 434408 - 05/20/2020
  1. Warning Letters

CLOSEOUT LETTER

Cenorin, LLC MARCS-CMS 434408 —

Reference #:
WL SEA 15-09
Product:
Medical Devices
Recipient:
Recipient Name
Mr. Fredric R. Radford
Recipient Title
CEO
Cenorin, LLC

6324 South 199th Place
Suite 107
Kent, WA 98032
United States

rradford@cenorin.com
Issuing Office:
Office of Medical Device and Radiological Health Operations (Division 3W)

United States

Dear Mr. Radford:

The Food and Drug Administration has completed evaluation of your firm’s corrective actions in response to our Warning Letter [WL SEA 15-09 dated February 12, 2015]. Based on our evaluation, it appears that you have addressed the violations contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.

This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.

Sincerely,
/S/
Jessica Mu
Director of Compliance Branch
Office of Medical Device and Radiological Health
Division 3/West

Back to Top